- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Generic Vs. Brand Name Drugs: Caylon Securities Conducts A Poll
Recent Articles by Ed Liston
- U.S. Equity Markets Preview (ARO, CF, LDK, NSM, PLL)
- Aeropostale, Inc.’s (ARO) Fourth-Quarter Profit Up By 44%
- Toyota Motor Corp.’s (TM) U.S. Sales Boosted By Discounts
- Warren Buffett’s Salary Remains Unchanged For 29th Straight Year (BRK.A)
- Discovery Financial Services (DFS) Expects A Loss In First-Quarter
CNBC
- RBC Capital Markets Sees STI At $50
- Fast Money Picks For March 12th (AA, BBY, X, XBI, CAT)
- Will Uncle Sam Kill A-Power's Tailwind? (SPWR)
- Mad Money Lightning Round: Jim Recommends ERTS, INCY, MNRO, CTSH, GST, CREE, GLW, NFLX
- Analyst Recommends Diana Shipping And Genco Shipping (DSX, GNK)
Company News
- Aeropostale, Inc.’s (ARO) Fourth-Quarter Profit Up By 44%
- Toyota Motor Corp.’s (TM) U.S. Sales Boosted By Discounts
- Discovery Financial Services (DFS) Expects A Loss In First-Quarter
- Pall Corporation’s (PLL) Second-Quarter Profits Below Expectations
- Agrium, Inc. (AGU) To Terminate $5.4 Billion Offer To Buy CF Industries (CF)
FDA
- Medtronic’s Epilepsy Device Fails FDA Test (MDT, CYBX)
- Thomas Weisel Partners More Than Double InterMune (ITMN) Price Target To $55
- InterMune (ITMN) Shares Jump 63% After FDA Announcement
- Five Biotech ETFs, Which One Is Worth A Look?
- FDA Approves Botox In Treatment Of Muscle Spasms
Markets
- Aeropostale, Inc.’s (ARO) Fourth-Quarter Profit Up By 44%
- Toyota Motor Corp.’s (TM) U.S. Sales Boosted By Discounts
- Discovery Financial Services (DFS) Expects A Loss In First-Quarter
- Pall Corporation’s (PLL) Second-Quarter Profits Below Expectations
- Agrium, Inc. (AGU) To Terminate $5.4 Billion Offer To Buy CF Industries (CF)
Media
Posted on 01/29/10 at 2:50pm by Ed Liston
Three out of four prescriptions in the U.S. are filled by generics.
CNBC's Mike Huckman reports that Caylon Securities has conducted a poll regarding the use of generic drugs. The study has come up with some interesting facts.
According to the report, 65% of the pharmacists expressed their concern about generic-drug safety. However, only 15% said that they place more trust on brand-name drugs than generics. 75% of the respondents said that the drug bottles should display the drug manufacturer's name and the name of the country where the drug was manufactured. Teva (NASdAQ: TEVA), Mylan (NASDAQ: MYL) and Pfizer (NYSE: PFE) Greenstone generic drug units emerged as the top three favorite generic drug manufacturers.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Goldman Sachs (GS) VIP List of Top Hedge Fund Holdings
- Pfizer Rejoins the Race For Ratiopharm (PFE, TEVA)
- Pfizer (PFE) Said To Bid As Much As $4.08 Billion For Ratiopharm
- Pfizer Inc Set To Enter the Growing Generic Drugs Market of Japan (PFE, TEVA)
- UBS Adds OXY, MYL, CSX To Most Preferred List; Removes APA, TEVA
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
